About Repare Therapeutics Inc.
https://www.reparerx.comRepare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.
CEO
Steve Forte CPA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BVF INC/IL
Shares:10.33M
Value:$26.87M
BLUE OWL CAPITAL HOLDINGS LP
Shares:3.44M
Value:$8.95M
ORBIMED ADVISORS LLC
Shares:3.32M
Value:$8.64M
Summary
Showing Top 3 of 54
About Repare Therapeutics Inc.
https://www.reparerx.comRepare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.62M ▲ | $10.49M ▼ | $3.26M ▲ | 28.04% ▲ | $0.08 ▲ | $3.48M ▲ |
| Q2-2025 | $250K ▲ | $18.03M ▼ | $-16.74M ▲ | -6.7K% ▼ | $-0.39 ▲ | $-19.03M ▲ |
| Q1-2025 | $0 | $26.6M ▼ | $-30.04M ▼ | 0% | $-0.71 ▼ | $-28.35M ▼ |
| Q4-2024 | $0 | $30.2M ▼ | $-28.67M ▲ | 0% | $-0.67 ▲ | $-28.08M ▲ |
| Q3-2024 | $0 | $34.13M | $-34.41M | 0% | $-0.81 | $-33.2M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $112.6M ▲ | $126.75M ▼ | $11.62M ▼ | $115.13M ▲ |
| Q2-2025 | $109.47M ▼ | $130.49M ▼ | $20.09M ▲ | $110.41M ▼ |
| Q1-2025 | $124.23M ▼ | $144.02M ▼ | $18.93M ▼ | $125.1M ▼ |
| Q4-2024 | $152.79M ▼ | $176.51M ▼ | $25.38M ▼ | $151.13M ▼ |
| Q3-2024 | $179.43M | $206.39M | $31.43M | $174.96M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.26M ▲ | $2.65M ▲ | $2.54M ▲ | $30K ▲ | $5.17M ▲ | $2.65M ▲ |
| Q2-2025 | $-16.74M ▲ | $-16.34M ▲ | $-586K ▼ | $0 ▼ | $-16.8M ▼ | $-16.34M ▲ |
| Q1-2025 | $-30.04M ▼ | $-29.13M ▼ | $28.79M ▼ | $79K ▲ | $-262K ▼ | $-29.13M ▼ |
| Q4-2024 | $-28.67M ▲ | $-27.32M ▲ | $31.59M ▲ | $1K ▼ | $4.18M ▲ | $-27.32M ▲ |
| Q3-2024 | $-34.41M | $-30.54M | $31.08M | $166K | $721K | $-30.54M |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 |
|---|---|---|
 SWITZERLAND | $0 ▲ | $10.00M ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ |
CEO
Steve Forte CPA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BVF INC/IL
Shares:10.33M
Value:$26.87M
BLUE OWL CAPITAL HOLDINGS LP
Shares:3.44M
Value:$8.95M
ORBIMED ADVISORS LLC
Shares:3.32M
Value:$8.64M
Summary
Showing Top 3 of 54